2008

In 2008, we identified the need to develop products for health care industry that not only eliminate bacteria but also viruses, fungi, mycobacteria, and spores. However, unlike existing solutions, we aimed for products that are non-contaminating and non-toxic, in other words, safe and biodegradable. Applying nanotechnology, we pioneered the development and manufacturing of the first nanoparticulate active ingredient. This bioselective, safe, and highly effective ingredient neutralizes any type of pathogenic microorganism.

We developed the first Antimicrobial System: Éviter®

With over 14 years of research and collaborations with Higher Education and Health Institutes, we position ourselves at the forefront of nanotechnological product development worldwide. Thanks to this innovation, we have already been granted a patent in Mexico, Arabia, and Argentina, for which we have been recognized as a success story by the IMPI (Mexican Institute of Industrial Property) for being a historic patent— the first granted in Mexico with coverage in over 140 countries.

On April 2015

as a platform for international projection, we founded Inmolecule International in the United Kingdom, focused on research and development, as well as establishing worldwide connections.

Since 2016, we have obtained patents in Mexico and subsequently in Israel, USA, Russia, Japan, South Korea, Chile, among others.

2021 - Our First Scientific Published Article

Our first scientific article is published by the Swiss scientific journal 'Journal of Nano Research,' describing the effectiveness of our nanomolecule as a safe and innovative virucide against SARS-CoV-2.

2022 - OUR SECOND ARTICLE!

This article is published in the American scientific journal 'Springer,' sharing the progress of our technological platform."

At present day,

we have opened new markets by extending our nano phytochemical platform to new categories, aiming to reach more people and protect them from pathogenic microorganisms.